

Susan Hess Ph.D.
Senior Patent Attorney

Novartis
Corporate Intellectual Property
One Health Plaza, Building
430
East Hanover NJ 07936-
1080

Tel (862) 778-7859
Fax (973) 781-8064
Internet: susan.hess
@group.novartis.com



Fax

**RECEIVED
CENTRAL FAX CENTER**

DEC 10 2003

OFFICIAL

Attention United States Patent and Trademark Office

Fax no. 703-872-9306
Number of pages including cover page — 23

Date December 4, 2003

Concerning U.S. Patent Application for
AMLOT ET AL.
Application No. 09/770,002
Our Case No. 4-30583A/30967/C1

Sir:

Please see attached.

Very truly yours,


A handwritten signature of Susan Hess in dark ink.
Susan Hess

SH:pmm

CONFIDENTIALITY NOTICE

THIS FAX CONTAINS CONFIDENTIAL INFORMATION WHICH MAY BE PRIVILEGED AND IS INTENDED SOLELY FOR THE USE OF THE ABOVE-NAMED RECIPIENT(S). IT MAY BE EXEMPT FROM DISCLOSURE UNDER APPLICABLE LAW. IF YOU ARE NOT AN INTENDED RECIPIENT OR PERSON RESPONSIBLE FOR DELIVERY OF THIS FAX TO AN INTENDED RECIPIENT, YOU ARE HEREBY NOTIFIED THAT YOU HAVE RECEIVED THIS FAX IN ERROR AND THAT ANY REVIEW, DISSEMINATION, DISCLOSURE, COPYING OR OTHER USE OF THIS FAX OR ITS CONTENTS IS STRICTLY PROHIBITED. IF YOU HAVE RECEIVED THIS FAX IN ERROR, PLEASE NOTIFY THE SENDER IMMEDIATELY BY TELEPHONE AT ONE OF THE FOLLOWING NUMBERS:

CASE 4-30583A

<u>CERTIFICATE OF FACSIMILE TRANSMISSION</u>		
I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being facsimile transmitted to the Patent and Trademark Office on the date shown below.		
<u>Susan Hess</u> Type or print name	<u></u> Signature	<u>December 4, 2003</u> Date

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF

Art Unit: 1644

AMLOT ET AL.

Examiner: Gerald Ewoldt

APPLICATION NO: 09/770,002

FILED: JANUARY 25, 2001

FOR: USE OF CD25 BINDING MOLECULES IN THE TREATMENT OF
RHEUMATOID ARTHRITIS OR SKIN DISEASES

MS: After Final
Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450


COMMUNICATION

Sir:

In a telephone call on December 2, 2003, the Examiner in charge of the above-identified case indicated that he did not receive a response to the Final Action mailed on April 28, 2003. Applicants informed the Examiner that a response was timely filed on October 28, 2003 along with a petition for a three month extension of time. The Examiner requested that we resubmit the response by facsimile. Attached hereto is the previously submitted response and the petition for extension of time, along with a copy of the date-stamped postcard returned from the PTO indicating that the response was timely filed on October 28, 2003. Applicants respectfully request that the presently filed papers upon their receipt be matched with the file and forwarded to the Examiner.

Respectfully submitted,

Novartis
Corporate Intellectual Property
One Health Plaza, Building 430
East Hanover, NJ 07936-1080
(862) 778-7859


Susan Hess
Attorney for Applicants
Reg. No. 37,350

Dat : December 4, 2003

Response Under 37 CFR §1.116
Expedited Procedure
Examining Group 1632

CASE 4-30583A

FILING BY "EXPRESS MAIL" UNDER 37 CFR 1.10	
EV335543080US Express Mail Label Number	OCTOBER 28, 2003 Date of Deposit
RECEIVED CENTRAL FAX CENTER	

DEC 10 2003

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF

Art Unit: 1644

AMLOT ET AL.

Examiner: Gerald Ewoldt

APPLICATION NO: 09/770,002

FILED: JANUARY 25, 2001

FOR: USE OF CD25 BINDING MOLECULES IN THE TREATMENT OF
RHEUMATOID ARTHRITIS OR SKIN DISEASES

MS: After Final
Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450

OFFICIALRESPONSE AFTER FINAL REJECTION

Sir:

This is in response to the Office Action dated April 28, 2003 having a shortened three month period for response which expired on July 28, 2003. Applicants enclose herewith a petition for a three month extension of time together with authorization to deduct the appropriate fee.

Remarks begin on page 2 of this paper.